↓ Skip to main content

Preventive drugs in the last year of life of older adults with cancer: Is there room for deprescribing?

Overview of attention for article published in Cancer (0008543X), March 2019
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
22 news outlets
blogs
2 blogs
twitter
100 tweeters
facebook
3 Facebook pages

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
24 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Preventive drugs in the last year of life of older adults with cancer: Is there room for deprescribing?
Published in
Cancer (0008543X), March 2019
DOI 10.1002/cncr.32044
Pubmed ID
Authors

Lucas Morin, Adam Todd, Stephen Barclay, Jonas W. Wastesson, Johan Fastbom, Kristina Johnell

Abstract

The continuation of preventive drugs among older patients with advanced cancer has come under scrutiny because these drugs are unlikely to achieve their clinical benefit during the patients' remaining lifespan. A nationwide cohort study of older adults (those aged ≥65 years) with solid tumors who died between 2007 and 2013 was performed in Sweden, using routinely collected data with record linkage. The authors calculated the monthly use and cost of preventive drugs throughout the last year before the patients' death. Among 151,201 older persons who died with cancer (mean age, 81.3 years [standard deviation, 8.1 years]), the average number of drugs increased from 6.9 to 10.1 over the course of the last year before death. Preventive drugs frequently were continued until the final month of life, including antihypertensives, platelet aggregation inhibitors, anticoagulants, statins, and oral antidiabetics. Median drug costs amounted to $1482 (interquartile range [IQR], $700-$2896]) per person, including $213 (IQR, $77-$490) for preventive therapies. Compared with older adults who died with lung cancer (median drug cost, $205; IQR, $61-$523), costs for preventive drugs were higher among older adults who died with pancreatic cancer (adjusted median difference, $13; 95% confidence interval, $5-$22) or gynecological cancers (adjusted median difference, $27; 95% confidence interval, $18-$36). There was no decrease noted with regard to the cost of preventive drugs throughout the last year of life. Preventive drugs commonly are prescribed during the last year of life among older adults with cancer, and often are continued until the final weeks before death. Adequate deprescribing strategies are warranted to reduce the burden of drugs with limited clinical benefit near the end of life.

Twitter Demographics

The data shown below were collected from the profiles of 100 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 21%
Student > Doctoral Student 5 21%
Other 4 17%
Student > Master 3 13%
Student > Bachelor 2 8%
Other 5 21%
Readers by discipline Count As %
Medicine and Dentistry 14 58%
Unspecified 3 13%
Nursing and Health Professions 2 8%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Neuroscience 2 8%
Other 1 4%

Attention Score in Context

This research output has an Altmetric Attention Score of 235. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 September 2019.
All research outputs
#56,192
of 13,864,530 outputs
Outputs from Cancer (0008543X)
#86
of 9,951 outputs
Outputs of similar age
#1,958
of 262,546 outputs
Outputs of similar age from Cancer (0008543X)
#5
of 137 outputs
Altmetric has tracked 13,864,530 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,951 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.7. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,546 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 137 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.